CYTO Altamira Therapeutics Ltd: Enterprise Value to EBITDA Ratio
The market for innovative nasal delivery systems for RNA drugs is currently taking shape, establishing a foundation for future licensing sales. The available price action vector with the indicator helps track this trend. Altamira Therapeutics (CYTO) operates a business that is not subject to seasonality or market cycles, possessing high resilience. Simultaneously, Altamira Therapeutics (CYTO) is implementing eco-friendly packaging and reducing medical waste through needle-free technologies.
Comprehensive metric breakdowns and analytics for altamiratherapeutics.com (CYTO)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Altamira Therapeutics|CYTO - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Altamira Therapeutics Ltd.|CYTO - Company Aggregate Debts|Debt to Book Capitalization Ratio Altamira Therapeutics|CYTO - Company Long-Term Debt|Company Current Liabilities Altamira Therapeutics|Quick Ratio altamiratherapeutics.com
- financial results and valuation multiples details:
CYTO - Net Profit|Expected Profit Altamira Therapeutics|CYTO - Price to Earnings Ratio|Forward P/E Multiple Altamira Therapeutics Ltd.|CYTO - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Altamira Therapeutics|CYTO - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Altamira Therapeutics|CYTO - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months altamiratherapeutics.com|CYTO - Earnings per share increase in current year|Expected earnings per share growth for next year Altamira Therapeutics
Fundamental company analysis:CYTO (Auris Medical)
EV/EBITDA assesses business value inclusive of net debt relative to operating profit, allowing for the determination of an asset's real value without the influence of tax burdens. By analyzing the current EV/EBITDA ratio with debt, an investor can see how the optimization of RNA research supply chains impacts the market capitalization of Altamira Therapeutics (CYTO). The stability of this metric confirms the efficiency of logistics networks and the overall financial resilience of the company.
Who Altamira Therapeutics competes with
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals, Inc.)|EV/EBITDA Multiple MannKind Corp MNKD|AMPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PCRX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SPRY (ARS Pharmaceuticals) - Enterprise Value to EBITDA Ratio|TBPH: Enterprise Value to Operating Income Before Depreciation Ratio|AQST (Aquestive Therapeutics, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple scPharma|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tectonic Therapeutic, Inc. (TECX)|Enterprise Value to EBITDA Ratio Tonix Pharmaceuticals Holding TNXP|EV/EBITDA Multiple SXTC (China SXT Pharmaceuticals, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Eupraxia Pharmaceuticals, Inc. (EPRX)|BHST - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation EXOZ (Invizyne Technologies)|ORMP: EV/EBITDA Multiple|Entera Bio (ENTX) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio HYFT|ABVC: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio CPIX (Cumberland Pharmaceuticals Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio QNTM|EV/EBITDA Multiple FGEN (FibroGen Corp)|Business Value to Operating Income Before Depreciation TELO|Rani Therapeutics Inc - EV/EBITDA Multiple|Company Value to EBITDA Synergy CHC Corp|rallybio.com (RLYB) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Lexaria Bioscience Corp. - Business Value to Operating Income Before Depreciation|PULM (Pulmatrix Corp) - EV/EBITDA Multiple|EV/EBITDA Multiple Pheton|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aptorum Group Limited (APM)|LYRA: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple IBO (Impact BioMedical)|TNF Pharmaceuticals Inc. (TNFA) - Company Value to EBITDA|YCBD: Enterprise Value to EBITDA Ratio|PRFX - EV/EBITDA Multiple|LIPO (Lipella Pharmaceuticals) - Enterprise Value to EBITDA Ratio|OPTN: Enterprise Value to Operating Income Before Depreciation Ratio|PIRS (Pieris Pharmaceuticals, Inc.) - EV/EBITDA Multiple|Procaps Group (PROC) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PTPI|Enterprise Value to EBITDA Ratio Qilian International Corp QLI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|Total Company Value to Operating Income Before Depreciation Ratio tffpharma.com (TFFP)
